Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab plus rituximab versus placebo plus rituximab in adults with persistent or chronic immune thrombocytopenia
2021-000006-16Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Belimumab + rituximab with Placebo + rituximab (2 arms). Primary endpoint: Overall response rate at week 52. Started Nov 2021; status: active.
02
Drugs
belimumabrituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2021-000006-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000006-16.